Refractory Acute Biphenotypic Leukemia
4 clinical trials · Condition
◉ Watch Refractory Acute Biphenotypic Leukemia
| Record | Firm | Date |
|---|---|---|
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767) | University of Washington | 2022-02-04 |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 (NCT04874194) | M.D. Anderson Cancer Center | 2021-12-17 |
| Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT04975919) | M.D. Anderson Cancer Center | 2021-09-29 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (NCT04526795) | M.D. Anderson Cancer Center | 2021-04-09 |
Track Refractory Acute Biphenotypic Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.